Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SOC-1 trial: what clinicians have said so far
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
- NCT01611766 ↗
- Unknown
- Shanghai Gynecologic Oncology Group
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on SOC-1 (platinum-sensitive relapsed ovarian cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SOC-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 10 posts on X | |
| 5 podcast episodes | |
| 2 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Ovarian Epithelial Cancer Recurrent; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
- Interventions
- Secondary Cytoreductive Surgery; Salvage Chemotherapy
- Arms
- secondary cytoreductive surgery · Experimental
- Salvage Chemotherapy · Active comparator
- Enrollment
- 356 (estimated)
- Primary outcomes
- Overall survival
- Progression-free survival
- Sponsor
- Shanghai Gynecologic Oncology Group with Fudan University, Zhejiang Cancer Hospital, Shanghai Zhongshan Hospital, Sun Yat-sen University
- Start
- Jul 19, 2012
- Primary completion
- Dec 2019
- Results posted
- No
- Registry record
- NCT01611766 · updated Jun 10, 2021
Publications
linked from the registry- Jiang R, Feng Y, Chen Y, Cheng X, Shi T, Gao W, Jia H, Jiang S, Guo Y, Huang X, Tu D, Zhang Y, Yang H, Zhang P, Liu J, Zhu J, Zang R; SOC-1 Investigators. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat Med. 2024 Aug;30(8):2181-2188. doi: 10.1038/s41591-024-02981-0. Epub 2024 Jun 1. PubMed 38824243
- Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. PubMed 33705695